SeaSpine — Merger or Acquisition (November 2022)
18 slides from SeaSpine's merger presentation, Nov 1, 2022

Slide 1: Stronger Together: Building a Leading Global Spine & Orthopedics Company
Stronger Together: Building a Leading Global Spine & Orthopedics Company November 1, 2022

Slide 2: Forward-Looking Statements
Forward-Looking Statements This communication contains statements which, to the extent they are not statements of historical or present fact, constitute “forward-looking statements” under the securities laws. From time to time, oral or written forward-looking statements may also be included in other

Slide 3: Additional Information & Where to Find It
Additional Information & Where to Find It In connection with the proposed transaction, Orthofix intends to file with the SEC a registration statement on Form S-4, which will include a document that serves as a prospectus of Orthofix and a joint proxy statement of Orthofix and SeaSpine (the “joint pr

Slide 4: Complementary & Compelling Strengths
Complementary & Compelling Strengths Next generation Unique 7D Flash Surgical differentiated artificial Navigation System cervical disc Rapid product innovation #1 prescribed bone growth (1) driving market-share taking stimulator portfolio in the with 45+ product launches U.S. since 2018 Market lead

Slide 5: Transformational Merger with Significant Strategic & Financial Benefits
One of the Highly complementary industry’s broadest spine & orthopedics biologics & regenerative portfolios technology offerings Transformational Merger with Significant Strategic Accelerated adoption rengthened U.S. & Financial Benefits of innovative and international differentiated technologies co

Slide 6: Transaction Summary
Transaction Summary All-stock merger of equals: SeaSpine shareholders receive 0.4163 shares of Orthofix common stock per Transaction share of SeaSpine common stock Structure Pro forma ownership: Approximately 56.5% Orthofix / Approximately 43.5% SeaSpine 9-member board of directors Executive Chairma

Slide 7: Expected Significant Growth & Value Creation
Expected Significant Growth & Value Creation Revenue Growth Complementary portfolios to drive projected double$ millions Year 3 digit growth post-integration period Significant Cost Synergies Revenue (1) ~$1,000 Leveraging combined infrastructures expected to generate $40M(3) in annualized cost savi

Slide 8: Combination of Companies Individually Well Positioned for Growth
Combination of Companies Individually Well Positioned for Growth 3-Year Revenue Growth Drivers Orthofix Drivers to Low Double-Digit Growth SeaSpine Drivers to Sustain High-Teens Growth DD Spine Fixation growth from 3 – 5 product and procedure launches Continued share taking at >5x market growth in s

Slide 9: Complementary Portfolios Across Growing Markets
Biologics Bone Growth Therapies Biologics & Regenerative Technologies Complementary Spinal Orthopedics Implants Portfolios Bridging Motion Preservation Limb Reconstruction Spine Fixation Deformity Correction Across Growing Enabling Markets Technologies Surgical Navigation System Preoperative Plannin

Slide 10: Differentiated & Synergistic Enabling Technologies
Differentiated & Synergistic Enabling Technologies Enabling technologies that service the full continuum of surgical care — from preoperative planning through surgical navigation 7D FLASH™ OrthoNext™ Navigation System Preoperative Planning System 10

Slide 11: Leading Spine Portfolio
Leading Spine Portfolio Cervical Thoracolumbar Fixation Interbodies M6-C™ NorthStar® Firebird™ NXG Forza™ TI Complementary, innovative Artificial Cervical Disc Posterior Cervical Pedicle Screw Spinal Fixation 3D Interbody Ti Spacer System with suite of offerings that Fixation System System Nanovate™

Slide 12: Leading Orthopedic Limb Reconstruction & Deformity Correction Portfolio
Leading Orthopedic Limb Reconstruction & Deformity Correction Portfolio Complementary, innovative suite of offerings that Fitbone™ JPS™ TrueLok™ EVO GBeam™ comprehensively address Intramedullary Nail System Pediatric Plating System Fusion Beaming System high-growth orthopedic market segments with a

Slide 13: One of the Broadest Biologics & Regenerative Technology Offerings in the Industry
One of the Broadest Biologics & Regenerative Technology Offerings in the Industry CBM / Lyograft DBM Synthetics Growth factors Stimulation ™ ™ ™ Trinity Elite OsteoTorrent Opus Novosis™ CervicalStim™ Allograft with Demineralized Bone Osteoconductive Spinal Fusion Viable Cells Matrix Scaffold Therapy

Slide 14: Diversified & Strategic Business Mix in Growing Markets
Diversified & Strategic Business Mix in Growing Markets Orthofix SeaSpine Combined Company 27% 24% 35% 40% 44% $463M* $230M* $693M* 56% 13% 15% 23% 23% Bone Growth Therapies Biologics Spinal Implants + Enabling Tech. Orthopedics *LTM revenue as of September 30, 2022 14

Slide 15: Combined Company Global Commercial Reach
Combined Company Global Commercial Reach Products Distributed in $136M* 68 International countries Global manufacturing & R&D footprint $557M* ~1,600 US employees 6 Primary company offices continents Countries of distribution *LTM revenue as of September 30, 2022 15

Slide 16: Foundation to Invest In, Strengthen & Attract Top Commercial Channel Partners
Foundation to Invest In, Strengthen & Attract Top Commercial Channel Partners Portfolio Resources Pipeline

Slide 17: Meaningful Revenue & Cost Synergy Opportunities
Meaningful Revenue & Cost Synergy Opportunities Est. Revenue Synergies: >$25M Working Capital and CapEx Synergies >$200M base of complementary revenue between motion preservation, 7D Efficiencies through economies of enabling technologies, and BGT creates immediate pull-through opportunity scale in

Slide 18: Transformational Merger with Significant Strategic & Financial Benefits
Transformational Merger with Significant Strategic & Financial Benefits Highly complementary spine & One of the industry’s broadest biologics orthopedics portfolios & regenerative technology offerings Accelerated adoption of innovative and Strengthened U.S. & differentiated technologies across inter
Source: SEC EDGAR · 425 filed Nov 1, 2022


